PREVENTION OF FETAL ALCOHOL SYNDROME WITH NOVEL PEPTIDES

ABSTRACT OF THE DISCLOSURE

This invention relates to a method for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol *in utero* with an ADNF polypeptide. In particular, the present invention relates to a method of reducing a condition associated

5   with fetal alcohol syndrome in a subject who is exposed to alcohol *in utero* with a combination of ADNF I and ADNF III polypeptides. The present invention further relates to a method for reducing neuronal cell death by contacting neuronal cells with a combination of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a combination of ADNF I and ADNF

10   III polypeptides.

SF 201015 v2